title: Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.
abstract: OBJECTIVE
  Osteonecrosis of the jaw (ONJ) presents a severe side-effect of intravenous bisphosphonate (i.v. BP) treatment; yet, the pathoethiological influence of the underlying disease which indicated that treatment remains unclear.
  
  
  METHODS
  We studied a large register of subjects who suffered an ONJ (n = 356) under i.v. BP therapy and characterized them according to underlying diseases and BP intake. By using claims data, we analysed indications in the general public in a cohort of new users of i.v. BPs (n = 1,075) in ambulatory care. For the years 2004-2006, both data sources were compared to indirectly assess the disease-specific risk for the development of an ONJ. We further assessed disease-specific survival after treatment initiation.
  
  
  RESULTS
  Patients with multiple myeloma were found more often, in the ONJ register, than were treated in real life (males: 36.4% vs. 16.2%; females: 27.8% vs. 6.5%) while the proportions of patients with prostate or breast cancer were as expected, and malignancies with low survival rates were strongly underrepresented. No patients with osteoporosis were reported to the ONJ register despite accounting for 18.8% of all the treated females in the general public.
  
  
  CONCLUSIONS
  The pattern of diagnoses that indicated i.v. BP treatment in patients who suffered an ONJ is different from what would be expected when looking at indications in the general public. Each underlying disease may, hence, have its own inherent risk to develop an ONJ due to varying life-expectancies and overall oncological treatment regimes including the interval and type of i.v. BP application.
authors.affiliation: Centre of Muscle and Bone Research (ZMK), Charité University Medicine, Campus Benjamin Franklin, Hindenburgdamm 130, 12200, Berlin, Germany. tatjana.jung@charite.de
authors.forename: Tatjana I
authors.initials: TI
authors.lastname: Jung
authors.forename: Falk
authors.initials: F
authors.lastname: Hoffmann
authors.forename: Gerd
authors.initials: G
authors.lastname: Glaeske
authors.forename: Dieter
authors.initials: D
authors.lastname: Felsenberg
mesh_terms: D017668:Age of Onset; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004198:Disease Susceptibility / Q000453:epidemiology / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D012042:Registries; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references.citation: Oncology. 2009;76(3):209-11
references.pmid: 19212145
references.citation: J Oral Maxillofac Surg. 2004 May;62(5):527-34
references.pmid: 15122554
references.citation: J Bone Miner Res. 2008 Jun;23(6):826-36
references.pmid: 18558816
references.citation: J Clin Epidemiol. 2006 Oct;59(10):1110-4
references.pmid: 16980152
references.citation: J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
references.pmid: 12966493
references.citation: Ann Oncol. 2009 Mar;20(3):600-1
references.pmid: 19188135
references.citation: Ann Oncol. 2009 Aug;20(8):1303-17
references.pmid: 19465418
references.citation: Clin Lymphoma Myeloma. 2008 Apr;8(2):111-6
references.pmid: 18501105
references.citation: J Natl Cancer Inst. 2007 Jul 4;99(13):1016-24
references.pmid: 17596574
references.citation: Cancer. 2000 Jun 15;88(12 Suppl):2961-78
references.pmid: 10898340
references.citation: J Am Dent Assoc. 2008 Jan;139(1):23-30
references.pmid: 18167381
references.citation: J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31
references.pmid: 17577497
references.citation: Bone. 1996 Feb;18(2):75-85
references.pmid: 8833200
references.citation: Oral Oncol. 2008 Sep;44(9):857-69
references.pmid: 18282788
references.citation: Bone. 2009 Jan;44(1):4-10
references.pmid: 18948230
references.citation: Clin Cancer Res. 2003 Aug 1;9(8):2893-7
references.pmid: 12912933
references.citation: Blood. 1999 Jan 1;93(1):300-5
references.pmid: 9864174
references.citation: J Oral Maxillofac Surg. 2006 Jun;64(6):917-23
references.pmid: 16713806
references.citation: Br J Haematol. 2007 Sep;138(5):563-79
references.pmid: 17686051
references.citation: Eur J Clin Pharmacol. 2002 Feb;57(12):883-90
references.pmid: 11936708
references.citation: Haematologica. 2006 Jul;91(7):968-71
references.pmid: 16757414
references.citation: J Bone Miner Res. 2007 Oct;22(10):1479-91
references.pmid: 17663640
references.citation: Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):896-903
references.pmid: 18666268
references.citation: J Clin Oncol. 2006 Mar 20;24(9):1475-7
references.pmid: 16549843
references.citation: Eur Urol. 2008 Nov;54(5):1066-72
references.pmid: 18602738
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug;104(2):186-93
references.pmid: 17448709
references.citation: Cancer Res. 2002 Nov 15;62(22):6538-44
references.pmid: 12438248
references.citation: Expert Opin Investig Drugs. 2005 Jan;14(1):45-55
references.pmid: 15709921
references.citation: J Evid Based Dent Pract. 2009 Mar;9(1):13-5
references.pmid: 19269608
references.citation: Med Oral Patol Oral Cir Bucal. 2007 Aug 01;12(4):E336-40
references.pmid: 17664922
references.citation: Leukemia. 2007 Jul;21(7):1545-8
references.pmid: 17410188
references.citation: Ortop Traumatol Rehabil. 2003 Apr 30;5(2):223-6
references.pmid: 18034010
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8580-7
references.pmid: 16314620
references.citation: J Am Dent Assoc. 2005 Dec;136(12):1658-68
references.pmid: 16383047